Immunosupressant recombinant fusion proteins

General description The adenomatous polyposis coli tumor suppressor gene is mutated (often deletion of the C-terminal portion of APC) in the inherited disease, familial adenomatous polyposis (FAP), and over 80% of colorectal cancers. C-APC 28.

General description The adenomatous polyposis coli tumor suppressor gene is mutated (often deletion of the C-terminal portion of APC) in the inherited disease, familial adenomatous polyposis (FAP), and over 80% of colorectal cancers. C-APC 28.

General description The adenomatous polyposis coli tumor suppressor gene is mutated (often deletion of the C-terminal portion of APC) in the inherited disease, familial adenomatous polyposis (FAP), and over 80% of colorectal cancers. Ali 12-28 can

Immunogen adenomatosis polyposis coli down-regulated 1-like Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive

Immunogen N-acylaminoacyl-peptide hydrolase recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are

Immunogen N-acylaminoacyl-peptide hydrolase recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are

Immunogen N-acylaminoacyl-peptide hydrolase recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are

Anti-APIP APAF1 interacting protein, 100ul UN 1687 6.1 PG2

Anti-APIP APAF1 interacting protein, 100ul UN 1687 6.1 PG2

Anti-APIP APAF1 interacting protein, 25ul UN 1687 6.1 PG2

Immunogen aprataxin and PNKP like factor Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in

Immunogen aprataxin and PNKP like factor recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are